Drug combination shows meaningful responses for malignant peritoneal mesothelioma patients
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients ...
Jul 14, 2021
0
5